Myocardial Infarction
Conditions
Keywords
Myocardial infarction, bio-collection, Imaging markers, biomarkers, STEMI, clinical outcomes
Brief summary
ST-segment elevation myocardial infarction (STEMI) is an acute condition that accounts for 75% of sudden deaths in adults over 35 years of age and more than half of all cases of chronic heart failure. However, the mechanism of myocardial infarction remains poorly understood. At present, there is no national information system for myocardial infarction, as there is for other diseases such as multiple sclerosis (OFSEP cohort). The purpose of this cohort is to enable studies and research projects to be carried out on the descriptive epidemiology of myocardial infarction, monitoring of patients undergoing treatment (safety, efficacy), quality of life and functional consequences of infarction, and research into new biological and imaging prognostic biomarkers. Its general objective is to provide researchers, hospital practitioners, medical interns, academics or industrialists with a quality epidemiological tool for research.
Interventions
OTHERMRI
1 MRI at 1 month with gadolinium injection
BIOLOGICALBiocollection
Biocollection from blood (H0, H4, H24, H48, 1 month, 1 year), urine (H48) and faecal (initial hospitalisation) samples.
BEHAVIORALQuality of life questionaries
EQ-5D-5L and HAD questionaries at 1 month and 1 year.
Sponsors
Hospices Civils de Lyon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Diagnosis of STEMI defined by ST segment elevation ≥ 0.2 mV in 2 contiguous leads on a 12-lead ECG. * Management in primary ACT * Prior oral informed consent followed by signed informed consent as soon as possible.
Exclusion criteria
* Diagnosis of STEMI not confirmed on angiography * Inability to give the subject informed information * Lack of coverage by a social security scheme * Obvious contraindication to injected magnetic resonance imaging (claustrophobia, pacemaker, defibrillator, or a metallic body (ferromagnetic), severe renal insufficiency (GFR\<30 ml/min), known allergy to the contrast medium ....) * Pregnant woman or woman of childbearing age without effective contraception, breastfeeding woman. * Deprivation of civil rights (curators, guardianship, safeguard of justice)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Research of potential new markers | 1 year | Biomarkers assays (prognosis and diagnosis) between inclusion and one-year follow-up (H0, H4, H24, H48, M1, M12 since emergency revascularisation) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Calculation of infarct size on MRI | 1 month | Measurement of reperfusion lesions on MRI (mass in grams) |
| Pharmacoepidemiology of myocardial infarction. | 5 years | Description and evolution of patients' medical treatment between hospital discharge and 5 years follow-up. |
| Events between inclusion and 5 years follow-up | 5 years | Time to a major adverse cardiovascular event |
Countries
France
Contacts
CONTACTThomas BOCHATON, Dr
CONTACTYvonne VARILLON
Outcome results
None listed